Zacks Investment Research downgraded shares of ENDOCYTE INC (ECYT) from OUTPERFORM to NEUTRAL on February 26, 2014, with a target price of $16.60.
Endocyte, Inc. is a biopharmaceutical company engaged in the development of therapies for the treatment of cancer and inflammatory diseases. The Company creates novel small molecule drug conjugates (SMDCs) and companion imaging diagnostics for personalized targeted therapies. Endocyte, Inc. is based in West Lafayette, Indiana.
Get all Zacks Research Reports and be alerted to fast-breaking buy and sell opportunities every trading day.
To get a free copy of the research report on ENDOCYTE INC (ECYT),
click here.
For more information about research offerings from Zacks Investment Research, visit
Zacks.com .
Be the first to comment